278 related articles for article (PubMed ID: 18794153)
1. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.
Tran MA; Gowda R; Sharma A; Park EJ; Adair J; Kester M; Smith NB; Robertson GP
Cancer Res; 2008 Sep; 68(18):7638-49. PubMed ID: 18794153
[TBL] [Abstract][Full Text] [Related]
2. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.
Cheung M; Sharma A; Madhunapantula SV; Robertson GP
Cancer Res; 2008 May; 68(9):3429-39. PubMed ID: 18451171
[TBL] [Abstract][Full Text] [Related]
3. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
[TBL] [Abstract][Full Text] [Related]
4. Melanoma prevention using topical PBISe.
Chung CY; Madhunapantula SV; Desai D; Amin S; Robertson GP
Cancer Prev Res (Phila); 2011 Jun; 4(6):935-48. PubMed ID: 21367959
[TBL] [Abstract][Full Text] [Related]
5. Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.
Sharma A; Madhunapantula SV; Gowda R; Berg A; Neves RI; Robertson GP
Am J Pathol; 2013 Apr; 182(4):1151-62. PubMed ID: 23416158
[TBL] [Abstract][Full Text] [Related]
6. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
7. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.
Shao Y; Aplin AE
Cancer Res; 2010 Aug; 70(16):6670-81. PubMed ID: 20647317
[TBL] [Abstract][Full Text] [Related]
8. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
9. Deregulated Akt3 activity promotes development of malignant melanoma.
Stahl JM; Sharma A; Cheung M; Zimmerman M; Cheng JQ; Bosenberg MW; Kester M; Sandirasegarane L; Robertson GP
Cancer Res; 2004 Oct; 64(19):7002-10. PubMed ID: 15466193
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Hoeflich KP; Herter S; Tien J; Wong L; Berry L; Chan J; O'Brien C; Modrusan Z; Seshagiri S; Lackner M; Stern H; Choo E; Murray L; Friedman LS; Belvin M
Cancer Res; 2009 Apr; 69(7):3042-51. PubMed ID: 19276360
[TBL] [Abstract][Full Text] [Related]
11. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
[TBL] [Abstract][Full Text] [Related]
12. Melanoma chemoprevention in skin reconstructs and mouse xenografts using isoselenocyanate-4.
Nguyen N; Sharma A; Nguyen N; Sharma AK; Desai D; Huh SJ; Amin S; Meyers C; Robertson GP
Cancer Prev Res (Phila); 2011 Feb; 4(2):248-58. PubMed ID: 21097713
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
14. Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.
Kuzu OF; Gowda R; Sharma A; Noory MA; Kardos G; Madhunapantula SV; Drabick JJ; Robertson GP
Cancer Biol Ther; 2018 Jan; 19(1):53-62. PubMed ID: 28853983
[TBL] [Abstract][Full Text] [Related]
15. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
[TBL] [Abstract][Full Text] [Related]
16. Targeting mutant (V600E) B-Raf in melanoma interrupts immunoediting of leukocyte functions and melanoma extravasation.
Liang S; Sharma A; Peng HH; Robertson G; Dong C
Cancer Res; 2007 Jun; 67(12):5814-20. PubMed ID: 17575149
[TBL] [Abstract][Full Text] [Related]
17. PRAS40 deregulates apoptosis in malignant melanoma.
Madhunapantula SV; Sharma A; Robertson GP
Cancer Res; 2007 Apr; 67(8):3626-36. PubMed ID: 17440074
[TBL] [Abstract][Full Text] [Related]
18. KIT Suppresses BRAF
Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic B-Raf(V600E) abrogates the AKT/B-Raf/Mps1 interaction in melanoma cells.
Zhang L; Shi R; He C; Cheng C; Song B; Cui H; Zhang Y; Zhao Z; Bi Y; Yang X; Miao X; Guo J; Chen X; Wang J; Li Y; Cheng X; Liu J; Cui Y
Cancer Lett; 2013 Aug; 337(1):125-32. PubMed ID: 23726842
[TBL] [Abstract][Full Text] [Related]
20. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
